Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
H U Group HoldingsTSE:4544 +0.24%72 PS Ratio is 0.77 as of Jul. 14, 2026, which is 1% above its 10-year median of 0.76. GuruFocus rates TSE:4544 with a GF Score™ of 72/100 and a GF Value™ of 円2,776.53 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, H U Group Holdings ranks better than 87.06% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, H U Group Holdings's share price is 円3352.00.
H U Group Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円4,374.98. Hence, H U Group Holdings's PS Ratio for today is 0.77.
The historical rank and industry rank for H U Group Holdings's PS Ratio or its related term are showing as below:
TSE:4544'
s PS Ratio Range Over the Past 10 Years
Min: 0.53 Med: 0.76 Max: 1.51
Current: 0.76
During the past 13 years, H U Group Holdings's highest PS Ratio was 1.51. The lowest was 0.53. And the median was 0.76.
TSE:4544's PS Ratio is ranked better than 87.06% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.81
vs TSE:4544: 0.76
H U Group Holdings Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of H U Group Holdings was 2.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -1.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 0.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 3.00% per year.
During the past 13 years, H U Group Holdings's highest 3-Year average Revenue per Share Growth Rate was 14.60% per year. The lowest was -5.10% per year. And the median was 4.10% per year.
Back to Basics: PS Ratio
H U Group Holdings (TSE:4544) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
H U Group Holdings PS Ratio Related Terms
H U Group Holdings PS Ratio Historical Data
* Premium members only.
The historical data trend for H U Group Holdings's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, H U Group Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H U Group Holdings PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, H U Group Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where H U Group Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
H U Group Holdings's Share Price of today is 円3352.00. H U Group Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円4,374.98.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
H U Group Holdings (TSE:4544) has a PS Ratio of 0.77 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on H U Group Holdings and its competitors. This is near median its historical median of 0.76. Over the past decade, H U Group Holdings' PS Ratio has ranged from 0.53 to 1.51. According to the industry distribution chart, H U Group Holdings ranks #26 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 12.9%.
Is H U Group Holdings' PS Ratio too high?
H U Group Holdings' current PS Ratio of 0.77 is near median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 1.51. The Medical Diagnostics & Research industry median PS Ratio is 2.81. H U Group Holdings' value of 0.77 is 72.6% below this industry median. Based on the distribution chart, H U Group Holdings ranks #26 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, H U Group Holdings has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does H U Group Holdings' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, H U Group Holdings ranks #26 out of 201 companies for PS Ratio. This places H U Group Holdings in the top 13% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.81. H U Group Holdings' value of 0.77 is 72.6% below this benchmark. Historically, H U Group Holdings' own PS Ratio has ranged from 0.53 to 1.51 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 2.81, H U Group Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.81, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H U Group Holdings's current PS Ratio of 0.77 is 72.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on H U Group Holdings and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H U Group Holdings's current PS Ratio is 0.77, which is near median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H U Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, H U Group Holdings (TSE:4544) is currently considered Modestly Overvalued. The stock's GF Value™ is 円2,776.53, compared to a current price of 円3,352.00 — trading 20.7% above its estimated fair value. The current PS Ratio is 0.77, which is near median its 10-year median of 0.76 and 72.6% below the Medical Diagnostics & Research industry median of 2.81. H U Group Holdings' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For H U Group Holdings (TSE:4544), the current PS Ratio is 0.77 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H U Group Holdings (TSE:4544) Overvalued in 2026?
Based on GuruFocus' analysis, H U Group Holdings stock appears to be overvalued.
The current stock price of 円3,352.00 is trading 20.7% above its estimated GF Value™ of 円2,776.53.
GuruFocus considers H U Group Holdings to be Modestly Overvalued.
Key valuation signals for TSE:4544:
PS Ratio: 0.77 (near median its 10-year median of 0.76)
GF Value™: 円2,776.53 vs. price of 円3,352.00 (20.7% above fair value)
Industry Position: 72.6% below the Medical Diagnostics & Research median (#26 of 201)
No single metric tells the full story. See the TSE:4544 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
H U Group Holdings Inc operates in the healthcare field, focusing on clinical laboratory testing and reagents. The company is engaged in four main businesses. The Clinical Laboratory Testing Business receives samples taken from patients at medical institutions to test for the disease and confirm the condition of the patient's health; In Vitro Diagnostics develops, manufactures, and sells testing reagents and equipment inside and outside Japan; Sterilization & Related Services Business provides a range of medical-related services including sterilization; and Emerging New Business & Others is a new business for future growth.
72GF Score
Get the complete analysis for TSE:4544
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4544 has been successfully added to your 
